Loading...
Loading...
Shares of
Spectrum Pharmaceuticals, Inc.SPPI were trading higher by nearly 5 percent late Friday morning after the company
announced that the U.S. Food and Drug Administration (FDA) has accepted its EOquin for New Drug Application (NDA) for review.
EOquin (apaziquone for intravesical instillation) is used for the treatment of non-muscle invasive bladder cancer.
Spectrum Pharmaceuticals added that the FDA indicated it plans to hold an advisory committee regarding the NDA and has set a target action date under the Prescrpition Drug User Fee Act (PDUFA) for December 11, 2016.© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in